REASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION

C. PASTOR MONDÉJAR1, C. INIESTA NAVALÓN1, A. MARTINEZ SOTO1, P. ORTIZ FERNANDEZ1, P. FERANDEZ-VILLACAÑAS FERNANDEZ1, L. RENTERO REDONDO2, C. CABALLERO REQUEJO1, M. GARCIA CORONEL1, I. SALAR VALVERDE1, E. URBIETA SANZ1, J. HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA, PHARMACY, MURCIA, SPAIN.

BACKGROUND AND IMPORTANCE
Secukinumab is an immunoglobulin G1 monoclonal antibody that selectively binds to the interleukin 17A and inhibits its interaction with the IL-A receptor. It is indicated in psoriasis (Ps), psoriatic arthritis (PsA) and ankylosing spondylitis in patients who no respond adequately to conventional treatments.

AIM AND OBJECTIVES
The aim of this study was to analyse the causes of secukinumab’s treatment discontinuation.

MATERIAL AND METHODS

RESULTS

The global persistence of secukinumab was 27.3 (IC95% 21.7-32.9) months. The media persistence of patients who suffered a primary failure was 5.1 months vs 21.7 months of a secondary failure. Diarrhoea represent the main cause along the adverse events (44%), follow by infections (33%), and other causes like astenia, fever or cefalea. Other reasons of discontinuation were: other illness (5.4%), remission (2.7%) and unknow causes (2.7%).

CONCLUSIONS AND RELEVANCE
Secukinumab shows a moderate percentage of treatment interruption, being the main cause a primary failure, follow by adverse events, being diarrhoea the more common among them. However, patients with secondary failure or who go on treatment, achieve a high persistence.